| scholarly article | Q13442814 |
| P50 | author | Alex Domling | Q73024340 |
| P2093 | author name string | Tad A Holak | |
| Katarzyna Magiera-Mularz | |||
| Markella Konstantinidou | |||
| Tryfon Zarganes-Tzitzikas | |||
| P2860 | cites work | B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion | Q22010866 |
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy | Q26745516 | ||
| The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors | Q27649885 | ||
| Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2 | Q27651269 | ||
| Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab | Q27702872 | ||
| Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab | Q27712488 | ||
| Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers | Q27853176 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy | Q28314934 | ||
| Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) | Q28822250 | ||
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy | Q29617774 | ||
| Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 | ||
| Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy | Q29964482 | ||
| Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. | Q33924667 | ||
| SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation | Q34331884 | ||
| Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses | Q34650346 | ||
| Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity | Q35762422 | ||
| Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. | Q36577841 | ||
| Therapeutic antibodies: successes, limitations and hopes for the future | Q37491236 | ||
| Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade | Q37686620 | ||
| Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy | Q37714274 | ||
| Targeting protein-protein interaction by small molecules | Q38155592 | ||
| Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. | Q38586991 | ||
| Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy | Q38641116 | ||
| Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015). | Q38883319 | ||
| High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1 | Q39296613 | ||
| Human PD-1 binds differently to its human ligands: a comprehensive modeling study | Q41340913 | ||
| Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant | Q42387009 | ||
| Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. | Q42700822 | ||
| Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab | Q47132253 | ||
| Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events | Q47164715 | ||
| Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. | Q47842052 | ||
| Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. | Q47999524 | ||
| A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use. | Q48194952 | ||
| Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. | Q48278713 | ||
| A cell culture model for T lymphocyte clonal anergy | Q67299314 | ||
| [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome] | Q89209743 | ||
| The immuno-oncology race: myths and emerging realities | Q89919944 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4840-4848 | |
| P577 | publication date | 2017-11-27 | |
| P1433 | published in | Angewandte Chemie International Edition | Q62023953 |
| P1476 | title | Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies? | |
| P478 | volume | 57 |
| Q89510454 | Approaches to PET Imaging of Glioblastoma |
| Q92372610 | CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not? |
| Q92095247 | Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics |
| Q64273980 | Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity |
| Q88643533 | Design, Synthesis, and Evaluation of Novel Immunomodulatory Small Molecules Targeting the CD40⁻CD154 Costimulatory Protein-Protein Interaction |
| Q92446491 | Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles |
| Q92084382 | Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists |
| Q95831756 | Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics |
| Q92416882 | Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity |
| Q93200030 | Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer |
| Q98895957 | Synthesis and Evaluation of Biphenyl-1,2,3-Triazol-Benzonitrile Derivatives as PD-1/PD-L1 Inhibitors |
| Q88922346 | Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions |
Search more.